5. | GLATT, S., UCB Pharma, Slough, Marea Britanie, BAETEN, D., UCB Pharma, Brussels, Belgia, BAKER, T., UCB Pharma, Slough, Marea Britanie, GRIFFITHS, M., UCB Pharma, Slough, Marea Britanie, IONESCU, L., UCB Pharma, Brussels, Belgia, LAWSON, A., UCB Pharma, Slough, Marea Britanie, MAROOF, A., UCB Pharma, Slough, Marea Britanie, OLIVER, R., UCB Pharma, Slough, Marea Britanie, POPA, S., dr., STRIMENOPOULOU, F., UCB Pharma, Slough, Marea Britanie, VAJJAH, P., UCB Pharma, Slough, Marea Britanie, WATLING, M., UCB Pharma, Slough, Marea Britanie, YEREMENKO, N., Национальный университет физического воспитания и спорта Украины, Ucraina, MIOSSEC, P., Université Lyon, Franţa, SHAW, S., UCB Pharma, Slough, Marea Britanie Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Annals of the Rheumatic Diseases. 2018, nr. , 532-523. ISSN - ISSNe 0003-4967. |